Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
V114 vs PNEUMOVAX 23 and PREVNAR 13 in Healthy Adults 50+
NCT01513551Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2012
- Primary completion
- Feb 2013
- Modality
- Split/Subunit Vaccines
01
Overview
A Phase 2 trial of pneumococcal 15-valent conjugate vaccine in pneumococcal infection, sponsored by Merck & Co.. Started Mar 2012; status: completed.
02
Drugs
pneumococcal 15-valent conjugate vaccine
03
Conditions
pneumococcal infection
Beyond the preview
Go deeper on NCT01513551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01513551.